Tocilizumab
[대역어] 토실리주맙
[용어속성] Drug
[용어속성] Drug
Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review
Original Paper
[키워드] 95% CI
95% CIs
acute kidney failure
acute renal failure
adjusted odds ratio
age
Analysis
baseline
C-reactive protein (CRP
calculate
Care
chart
clinical benefit
clinical effectiveness
Clinical outcome
cohort of patient
Comorbidities
Comorbidity
control group
control groups
COVID-19
COVID-19 diagnosis
COVID-19 pandemic
data-driven guideline
determine
dialysis
discharge
drug
Efficacy and safety
estimates
evaluate
Evidence
global pandemic
group
groups
HCQ
hospital
Hospitalization
hospitalized patient
Hydroxychloroquine
in-hospital mortality
initial
Intensive
intensive care
Invasive mechanical ventilation
mean difference
medication
multivariate logistic regression
no significant difference
objective
Odds ratio
offered
Patient
patients with COVID-19
performed
Randomized controlled trial
reduction in
reductions in
Result
retrospective cohort study
review
significantly higher
T Test
TCZ
Tocilizumab
Trial
use of hydroxychloroquine
was performed
with COVID-19
[DOI] 10.2196/21758 PMC 바로가기 [Article Type] Original Paper
[DOI] 10.2196/21758 PMC 바로가기 [Article Type] Original Paper
Immunosuppressive Drugs and COVID-19: A Review
Pharmacology
[키워드] “cytokine storm”
acute respiratory syndrome
analogue
ARDS
calcineurin inhibitors
case-control study
caused
clinical
clinical trial
cohort study
concerning
control group
coronavirus
Coronavirus disease 2019
Corticosteroid
Corticosteroids
COVID-19
detrimental
drug
Effect
Evidence
Host immune response
Human
IL-6 inhibitors
immunosuppressive drug
immunosuppressive drugs
In-vitro
indication
infection with SARS-CoV-2
inhibit
inhibitory effect
initial
mechanical ventilation
MERS-CoV
Middle East
Mortality
mTOR inhibitor
mTOR inhibitors
multiorgan failure
mycophenolic acid
observational study
overshoot
pandemic
patients with COVID-19
positive result
Prevent
Randomized controlled trial
RCTs
reduce mortality
Registered
respiratory syndrome coronavirus
Result
review
risk of bia
SARS-CoV
SARS-CoV-2
SARS-CoV-2 replication
standard care
Study protocol
Tocilizumab
viral replication
[DOI] 10.3389/fphar.2020.01333 PMC 바로가기 [Article Type] Pharmacology
[DOI] 10.3389/fphar.2020.01333 PMC 바로가기 [Article Type] Pharmacology
How to follow-up a patient who received tocilizumab in severe COVID-19: a case report
Case Report
[키워드] addition
approach
ARDS
Case report
change
characterized
Chloroquine
Clinical deterioration
Clinical improvement
Complete
COVID-19
current
Cytokine storm
Deterioration
Effectiveness
elevated
Follow-up
healthy
hyperinflammation
hypoxic
IL-6 receptor
immunomodulating agent
infections
Infectious disease
Initially
initiated
Long-term follow-up
long-term treatment
lung
lung tissue
magnitude
mechanical ventilation
mechanism
organ injury
overlapping
Patient
procedure
Prognosis
radiological
remained
Research
SARS-CoV-2
serum
severe COVID-19
Standard
Standard of care
suggested
survivor
Survivors
TCZ
therapy
Tocilizumab
toxicities
Toxicity
treated
Treatment
Warsaw
[DOI] 10.1186/s40001-020-00438-x PMC 바로가기 [Article Type] Case Report
[DOI] 10.1186/s40001-020-00438-x PMC 바로가기 [Article Type] Case Report
Efficacy of tocilizumab treatment in severely ill COVID-19 patients
Research Letter
[키워드] COVID-19
COVID-19 patient
Efficacy
Meta-analysis
Tocilizumab
Treatment
[DOI] 10.1186/s13054-020-03224-7 PMC 바로가기 [Article Type] Research Letter
[DOI] 10.1186/s13054-020-03224-7 PMC 바로가기 [Article Type] Research Letter
Overview of the First 6 Months of Clinical Trials for COVID-19 Pharmacotherapy: The Most Studied Drugs
COVID-19 약물 요법에 대한 첫 6개월간의 임상 시험 개요: 가장 많이 연구된 약물
Review
[키워드] affecting
Analysis
Azithromycin
Biology
candidate drug
candidate drugs
China
Chloroquine
clinical
clinical trial
clinical trial (2.172)
clinical trials
conditions
coronavirus (2019-nCoV)
COVID-19
COVID-19 (condition)
COVID-19 infection
defined
Diagnosis
drug
drugs
duplication
duplications
effective therapy
Effectiveness
Epidemiology
excessive immune response
focus
global effort
global efforts
Host
Hydroxychloroquine
identify
include
information
Ivermectin
Lopinavir
management
Month
MOST
other conditions
pandemic
Perspective
representing
Ritonavir
SARS-CoV-2
Spread
tested
therapy
Tocilizumab
treat
Treatment
Vaccine
virus
WHO
[DOI] 10.3389/fpubh.2020.00497 PMC 바로가기 [Article Type] Review
[DOI] 10.3389/fpubh.2020.00497 PMC 바로가기 [Article Type] Review
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia
코로나19 폐렴 환자에서 토실리주맙과 스테로이드 치료
Research Article
[키워드] 95%CI
adjusted
age
analyses
anti-inflammatory treatment
Comorbidities
Comorbidity
controls
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 pneumonia
Cox regression analysis
darunavir
death
defined
determine
difference
early treatment
Efficacy
Endpoint
endpoints
Evidence
failure
group
hazard
hazard ratio
Hospital admission
Hydroxychloroquine
immune response
IMPROVE
intravenously
Intubated
intubation
IQR
lead
male
median
median age
Methylprednisolone
non-intubated patient
non-intubated patients
not intubated
outcome
overall survival
PaO
Patient
patients with COVID-19
Pneumonia
primary endpoint
Propensity score
Ratio
Respiratory failure
Result
Ritonavir
Severe COVID-19 pneumonia
single-center study
Standard of care
steroid
steroid treatment
Steroids
subcutaneously
survival
Tocilizumab
treated patient
Treatment
treatment with tocilizumab
with COVID-19
[DOI] 10.1371/journal.pone.0237831 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.pone.0237831 PMC 바로가기 [Article Type] Research Article
A systematic review of trial registry entries for randomized clinical trials investigating COVID-19 medical prevention and treatment
Research Article
[키워드] antimalarial drug
antiviral drug
Blinding
category
chloroquine/hydroxychloroquine
clinical
convalescent plasma
country
COVID-19
drug
Favipiravir
FIVE
for inclusion
identify
immune
initiated
Intervention
investigated
management
meta-analyses
modulating
Mortality
multicenter trials
outcome
participant
Participants
Randomised clinical trials
randomized clinical trial
recruitment
registry
reported
Result
Sample
screened
single-arm design
stem cell
supportive therapy
systematic review
tested
the WHO
Tocilizumab
Treatment
treatment effects
Trial
trials
were excluded
[DOI] 10.1371/journal.pone.0237903 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.pone.0237903 PMC 바로가기 [Article Type] Research Article
Pharmacogenomics of COVID-19 therapies
Review Article
[키워드] ABCC2
adverse effects
Alter
association
Baricitinib
Chloroquine
clinical
Concentration
coronavirus disease
Corticosteroids
COVID-19
COVID-19 patient
CYP2C8
CYP2D6
drug
Effect
Efficacy
Efficacy and safety
Evidence
Favipiravir
FDA
food
genetic marker
Genetic markers
genetic variants
global pandemic
Hemolysis
high mortality
Hydroxychloroquine
hydroxychloroquine/chloroquine
information
inhibitors
interferon
Interferon beta-1b
labeling
liver
morbidity
notable
other variants
pharmacogenetics
pharmacogenomics
QT prolongation
Remdesivir
ribavirin
risk
ruxolitinib
searched
SLC28A2
SLC29A1
SLCO1A2
SLCO1B1
Therapies
therapy
Tocilizumab
Toxicity
variant
viral infection
website
[DOI] 10.1038/s41525-020-00143-y PMC 바로가기 [Article Type] Review Article
[DOI] 10.1038/s41525-020-00143-y PMC 바로가기 [Article Type] Review Article
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study
COVID-19 환자의 하이드록시클로로퀸 및 토실리주맙 요법 - 관찰 연구
Research Article
[키워드] adjusted
association
Azithromycin
benefit
caution
Chain Reaction
cohort study
Combination
COVID-19
Critically ill
critically ill patients
death
demonstrated
discharge
dose
Electronic health record
Electronic health records
Exploratory analysis
Hospitalization
Hospitalized
hospitalized COVID-19 patients
hospitalized patient
hospitalized patients
Hydroxychloroquine
ICU
ICU Patients
IL-6
inhibitor
inhibitor of IL-6
Mortality
New
no significant difference
no significant differences
Observational cohort study
Patient
polymerase chain
polymerase chain reaction
positive
propensity modeling
randomized trials
receiving
reduced
retrospective
SARS-CoV-2
survival
Tocilizumab
tocilizumab therapy
Treatment
Trial registration
USA
with COVID-19
[DOI] 10.1371/journal.pone.0237693 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.pone.0237693 PMC 바로가기 [Article Type] Research Article